

# Jean-SÃ©bastien Hulot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/221596/publications.pdf>

Version: 2024-02-01

238  
papers

20,769  
citations

13865

67  
h-index

10734

138  
g-index

258  
all docs

258  
docs citations

258  
times ranked

23978  
citing authors

#	ARTICLE	IF	CITATIONS
1	Induced pluripotent stem cells for modeling of cardiac arrhythmias. , 2022, , 247-273.		0
2	Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2022, 9, 519-530.	3.1	16
3	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2022, 24, 406-420.	7.1	22
4	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	3.8	30
5	Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. Lancet Rheumatology, The, 2022, 4, e24-e32.	3.9	34
6	RÃ©le des intÃ©grines dans la fibrose cardiaque. Medecine/Sciences, 2022, 38, 438-444.	0.2	0
7	Hypoxia promotes a perinatal-like progenitor state in the adult murine epicardium. Scientific Reports, 2022, 12, .	3.3	3
8	Potent human broadly SARS-CoV-2 neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. Journal of Experimental Medicine, 2022, 219, .	8.5	34
9	Endothelial Cell Indoleamine 2, 3-Dioxygenase 1 Alters Cardiac Function After Myocardial Infarction Through Kynurenine. Circulation, 2021, 143, 566-580.	1.6	33
10	Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. Lancet Rheumatology, The, 2021, 3, e40-e48.	3.9	32
11	HFpEF: Should We Consider Diabetic Patients Separately?. Journal of the American College of Cardiology, 2021, 77, 420-422.	2.8	6
12	Proteinuria and Clinical Outcomes in Hospitalized COVID-19 Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 514-521.	4.5	29
13	Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 295-304.	10.7	232
14	Cardiac performance in patients hospitalized with COVID-19: a 6-month follow-up study. ESC Heart Failure, 2021, 8, 2232-2239.	3.1	40
15	Cytotoxic CD8+ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling. Nature Communications, 2021, 12, 1483.	12.8	73
16	Visual lung damage CT score at hospital admission of COVID-19 patients and 30-day mortality. European Radiology, 2021, 31, 8354-8363.	4.5	20
17	Generation of iPSC line from MYH7 R403L mutation carrier with severe hypertrophic cardiomyopathy and isogenic CRISPR/Cas9 corrected control. Stem Cell Research, 2021, 52, 102245.	0.7	8
18	Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019. Clinical Infectious Diseases, 2021, 73, e1337-e1344.	5.8	35

#	ARTICLE	IF	CITATIONS
19	Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 1141-1158.	1.9	4
20	Cardiac Organoids to Model and Heal Heart Failure and Cardiomyopathies. <i>Biomedicines</i> , 2021, 9, 563.	3.2	10
21	Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity. <i>PLoS ONE</i> , 2021, 16, e0252026.	2.5	12
22	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2021, 117, 2148-2160.	3.8	26
23	Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1847-1855.	1.8	18
24	Association between coronary artery calcifications and 6-month mortality in hospitalized patients with COVID-19. <i>Diagnostic and Interventional Imaging</i> , 2021, 102, 717-725.	3.2	11
25	Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine. <i>Frontiers in Immunology</i> , 2021, 12, 701273.	4.8	5
26	Association Between Psychological Distress, Cognitive Complaints, and Neuropsychological Status After a Severe COVID-19 Episode: A Cross-Sectional Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 725861.	2.6	31
27	When Natural Peptides Meet Artificial Intelligence to Improve Risk Prediction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1632-1634.	2.8	0
28	Cardiometabolic Disorders and the Risk of Critical COVID-19 as Compared to Influenza Pneumonia. <i>Journal of Clinical Medicine</i> , 2021, 10, 4618.	2.4	4
29	Do Anxiety and Depression Predict Persistent Physical Symptoms After a Severe COVID-19 Episode? A Prospective Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 757685.	2.6	29
30	Combinatorial, additive and dose-dependent drug-microbiome associations. <i>Nature</i> , 2021, 600, 500-505.	27.8	102
31	CRISPR/Cas9 gene-editing strategies in cardiovascular cells. <i>Cardiovascular Research</i> , 2020, 116, 894-907.	3.8	40
32	Assessment of signal quality measured with a smart 12-lead ECG acquisition T-shirt. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12682.	1.1	33
33	Do we need a new P2Y12 receptor antagonist?. <i>European Heart Journal</i> , 2020, 41, 3141-3143.	2.2	6
34	Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. <i>Arthritis Research and Therapy</i> , 2020, 22, 223.	3.5	18
35	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1966-1983.	7.1	184
36	Anti-integrin $\alpha$ v therapy improves cardiac fibrosis after myocardial infarction by blunting cardiac PW1+ stromal cells. <i>Scientific Reports</i> , 2020, 10, 11404.	3.3	28

#	ARTICLE	IF	CITATIONS
37	Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors. <i>JACC: CardioOncology</i> , 2020, 2, 511-514.	4.0	8
38	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). <i>European Journal of Heart Failure</i> , 2020, 22, 2272-2289.	7.1	92
39	Obesity Doubles Mortality in Patients Hospitalized for Severe Acute Respiratory Syndrome Coronavirus 2 in Paris Hospitals, France: A Cohort Study on 5,795 Patients. <i>Obesity</i> , 2020, 28, 2282-2289.	3.0	76
40	Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. <i>Nature</i> , 2020, 581, 310-315.	27.8	283
41	Curative anticoagulation prevents endothelial lesion in COVID-19 patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2391-2399.	3.8	66
42	Reply. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1495-1496.	2.9	0
43	Suppression of Hematopoiesis in Recurrent Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 916-918.	2.8	3
44	Sequential nephron blockade with combined diuretics improves diastolic function in patients with resistant hypertension. <i>ESC Heart Failure</i> , 2020, 7, 2561-2571.	3.1	5
45	Hole of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation (<scp>HFA</scp>), the <scp>E</scp>uropean <scp>A</scp>ssociation of <scp>C</scp>ardiovascular <scp>I</scp>maging (<scp>EACVI</scp>) and the <scp>Cardio-Oncology C</scp>ouncil of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology (<scp>ESC</scp>). <i>European Journal of Heart Failure</i> , 2020, 22, 1504-1524.	7.1	234
46	Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 621-630.	2.9	28
47	COVID-19 in patients with cardiovascular diseases. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 225-226.	1.6	32
48	miRNA-Based Therapeutics for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1801-1803.	2.8	5
49	Androgenic Effects on Ventricular Repolarization. <i>Circulation</i> , 2019, 140, 1070-1080.	1.6	67
50	Reduced risk of cancer among low-dose aspirin users: Data from French health care databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1258-1266.	1.9	12
51	3444 Development of human engineered cardiac tissue (hECT)-based screening assay to explore cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 8-8.	0.6	0
52	Cardiomyocyte-Specific STIM1 (Stromal Interaction Molecule 1) Depletion in the Adult Heart Promotes the Development of Arrhythmogenic Discordant Alternans. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007382.	4.8	21
53	Towards Precision Medicine With Human iPSCs for Cardiac Channelopathies. <i>Circulation Research</i> , 2019, 125, 653-658.	4.5	53
54	Emerging Drug Classes and Their Potential Use in Hypertension. <i>Hypertension</i> , 2019, 74, 1075-1083.	2.7	46

#	ARTICLE	IF	CITATIONS
55	ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure. <i>Cardiovascular Research</i> , 2019, 115, 488-500.	3.8	90
56	Modeling Cardiomyopathies with iPSCs. <i>Current Human Cell Research and Applications</i> , 2019, , 73-95.	0.1	0
57	Modulation of chromatin remodeling proteins SMYD1 and SMARCD1 promotes contractile function of human pluripotent stem cell-derived ventricular cardiomyocyte in 3D-engineered cardiac tissues. <i>Scientific Reports</i> , 2019, 9, 7502.	3.3	8
58	Modeling Cardiac Arrhythmias With Organoids. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2325-2327.	2.8	11
59	Design and Validation of an Automated Process for the Expansion of Peripheral Blood-Derived CD34+ Cells for Clinical Use After Myocardial Infarction. <i>Stem Cells Translational Medicine</i> , 2019, 8, 822-832.	3.3	11
60	Cardiac inflammatory CD11b/c cells exert a protective role in hypertrophied cardiomyocyte by promoting TNFR2- and Orai3- dependent signaling. <i>Scientific Reports</i> , 2019, 9, 6047.	3.3	15
61	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , 2019, 40, 2155-2163.	2.2	195
62	Long-Term Evolution of Premature Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1868-1878.	2.8	81
63	Opioid-related genetic polymorphisms do not influence postoperative opioid requirement. <i>European Journal of Anaesthesiology</i> , 2018, 35, 496-504.	1.7	12
64	The lipodystrophic hotspot lamin A p.R482W mutation deregulates the mesodermal inducer T/Brachyury and early vascular differentiation gene networks. <i>Human Molecular Genetics</i> , 2018, 27, 1447-1459.	2.9	34
65	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end pointsâ€”Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). <i>American Heart Journal</i> , 2018, 198, 152-159.	2.7	24
66	Complex Association of Sex Hormones on Left Ventricular Systolic Function: Insight into Sexual Dimorphism. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 231-240.e1.	2.8	13
67	Perivascular fibrosis and the microvasculature of the heart. Still hidden secrets of pathophysiology?. <i>Vascular Pharmacology</i> , 2018, 107, 78-83.	2.1	23
68	Reg3Î² is associated with cardiac inflammation and provides prognostic information in patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2018, 258, 7-13.	1.7	9
69	2525 Development of human cell-based screening assays to detect subject-specific drug-response variability. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 9-10.	0.6	0
70	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Associationâ€”European Society of Cardiology. <i>European Heart Journal</i> , 2018, 39, 4243-4254.	2.2	171
71	CRISPRed Cardiomyocytes to Decrypt Variants of Uncertain Significance. <i>Journal of the American College of Cardiology</i> , 2018, 72, 76-78.	2.8	0
72	Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women. <i>JAMA Cardiology</i> , 2018, 3, 877.	6.1	30

#	ARTICLE	IF	CITATIONS
73	Outcome after revascularisation of acute myocardial infarction with cardiogenic shock on extracorporeal life support. <i>EuroIntervention</i> , 2018, 13, 2160-2168.	3.2	29
74	Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVEREST-2/ST-HIV study. <i>European Heart Journal</i> , 2017, 38, ehw583.	2.2	25
75	A PDGFR $\alpha$ -Mediated Switch toward CD9high Adipocyte Progenitors Controls Obesity-Induced Adipose Tissue Fibrosis. <i>Cell Metabolism</i> , 2017, 25, 673-685.	16.2	195
76	Functional Human Beige Adipocytes From Induced Pluripotent Stem Cells. <i>Diabetes</i> , 2017, 66, 1470-1478.	0.6	42
77	Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1534-1541.	7.1	75
78	Get Your Cell K.O. in the First Round. <i>Circulation Research</i> , 2017, 120, 1522-1523.	4.5	0
79	Effectiveness of heart rate control on hemodynamics in critically ill patients with atrial tachyarrhythmias managed by amiodarone. <i>Pharmacological Research</i> , 2017, 122, 118-126.	7.1	3
80	In Vitro Adherence Defines Therapeutic Cardiac Mesenchymal Cell Subpopulation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1839-1841.	2.8	0
81	Dietary Assessment in the MetaCardis Study: Development and Relative Validity of an Online Food Frequency Questionnaire. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2017, 117, 878-888.	0.8	32
82	Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai. <i>Pharmacogenomics</i> , 2017, 18, 1381-1386.	1.3	20
83	Impact of negative inotropic drugs on accuracy of diastolic stress echocardiography for evaluation of left ventricular filling pressure. <i>Scientific Reports</i> , 2017, 7, 9537.	3.3	5
84	Fibrogenic Potential of PW1/Peg3 Expressing Cardiac Stem Cells. <i>Journal of the American College of Cardiology</i> , 2017, 70, 728-741.	2.8	27
85	Differential Sarcomere and Electrophysiological Maturation of Human iPSC-Derived Cardiac Myocytes in Monolayer vs. Aggregation-Based Differentiation Protocols. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1173.	4.1	23
86	GENOME wide analysis of sotalol-induced IKr inhibition during ventricular REPOLarization, the GENEREPOL study: Lack of common variants with large effect sizes. <i>PLoS ONE</i> , 2017, 12, e0181875.	2.5	13
87	Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells. <i>ELife</i> , 2017, 6, .	6.0	82
88	Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2016, 115, 382-391.	3.4	14
89	Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 287-294.	4.7	22
90	MRP4 (ABCC4) as a potential pharmacologic target for cardiovascular disease. <i>Pharmacological Research</i> , 2016, 107, 381-389.	7.1	45

#	ARTICLE	IF	CITATIONS
91	Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. <i>European Heart Journal</i> , 2016, 37, 3282-3284.	2.2	60
92	miR-322 regulates insulin signaling pathway and protects against metabolic syndrome-induced cardiac dysfunction in mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 611-621.	3.8	32
93	Resident PW1 <sup>+</sup> Progenitor Cells Participate in Vascular Remodeling During Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2016, 118, 822-833.	4.5	34
94	Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloroquine levels. <i>Lupus</i> , 2016, 25, 735-740.	1.6	19
95	Gene therapy for the treatment of heart failure: promise postponed. <i>European Heart Journal</i> , 2016, 37, 1651-1658.	2.2	110
96	Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias. <i>Clinical Pharmacokinetics</i> , 2016, 55, 991-1002.	3.5	7
97	Cardiac <i>Stim1</i> Silencing Impairs Adaptive Hypertrophy and Promotes Heart Failure Through Inactivation of mTORC2/Akt Signaling. <i>Circulation</i> , 2016, 133, 1458-1471.	1.6	84
98	PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 374-383.	2.1	32
99	Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 43-53.	2.2	4
100	Epistatic Gene-Based Interaction Analyses for Glaucoma in eMERGE and NEIGHBOR Consortium. <i>PLoS Genetics</i> , 2016, 12, e1006186.	3.5	38
101	Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2015, 67, 2176-2184.	5.6	118
102	Effectiveness of gene delivery systems for pluripotent and differentiated cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 14067.	4.1	47
103	Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice. <i>Blood</i> , 2015, 126, 1823-1830.	1.4	51
104	Inhalable delivery of AAV-based MRP4/ABCC4 silencing RNA prevents monocrotaline-induced pulmonary hypertension. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 14065.	4.1	5
105	Overexpression of Cyclic Adenosine Monophosphate Effluent Protein MRP4 Induces an Altered Response to $\beta^2$ -Adrenergic Stimulation in the Senescent Rat Heart. <i>Anesthesiology</i> , 2015, 122, 334-342.	2.5	10
106	Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. <i>Nature Communications</i> , 2015, 6, 6955.	12.8	155
107	Emergence of Orai3 activity during cardiac hypertrophy. <i>Cardiovascular Research</i> , 2015, 105, 248-259.	3.8	36
108	Clinical implications of neuropharmacogenetics. <i>Revue Neurologique</i> , 2015, 171, 482-497.	1.5	3

#	ARTICLE	IF	CITATIONS
109	The pharmacogenetic control of antiplatelet response: candidate genes and <i>CYP2C19</i> . Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1599-1617.	3.3	22
110	Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. European Journal of Clinical Pharmacology, 2015, 71, 1059-1066.	1.9	14
111	Generating patient-specific induced pluripotent stem cells-derived cardiomyocytes for the treatment of cardiac diseases. Expert Opinion on Biological Therapy, 2015, 15, 1399-1409.	3.1	18
112	Development and Validation of a Rapid and Simple LC-MS/MS Method for Quantification of Vemurafenib in Human Plasma. Therapeutic Drug Monitoring, 2015, 37, 132-136.	2.0	8
113	Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. European Journal of Clinical Pharmacology, 2015, 71, 1315-1324.	1.9	31
114	Pharmacology and mechanisms of action of new oral anticoagulants. Fundamental and Clinical Pharmacology, 2015, 29, 10-20.	1.9	33
115	TNFR2-mediated Survival via Orail-dependent Calcium Influx in Compensated Cardiac Hypertrophy. FASEB Journal, 2015, 29, LB486.	0.5	0
116	Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. Lupus Science and Medicine, 2014, 1, e000027.	2.7	54
117	Impact of Inodilator Drugs on Echocardiographic Assessments of Left Ventricular Filling Pressure in Patients With Decompensated End-Stage Heart Failure*. Critical Care Medicine, 2014, 42, 2508-2517.	0.9	9
118	Corrigendum to: '2013 ESC guidelines on the management of stable coronary artery disease'. European Heart Journal, 2014, 35, 2260-2261.	2.2	11
119	Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEB Journal, 2014, 28, 644-654.	0.5	148
120	Antiplatelet drug interactions with proton pump inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 175-189.	3.3	35
121	Considerations for pre-clinical models and clinical trials of pluripotent stem cell-derived cardiomyocytes. Stem Cell Research and Therapy, 2014, 5, 1.	5.5	62
122	Clustering of Acute and Subacute Stent Thrombosis Related to the Introduction of Generic Clopidogrel. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 201-208.	2.0	15
123	Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2014, 100, 230-235.	2.8	32
124	Modeling CVD in Human Pluripotent Cells by Genome Editing. Journal of the American College of Cardiology, 2014, 64, 460-462.	2.8	9
125	Urinary coproporphyrin $\text{I}/\text{III}$ ratio as a surrogate for <i>MRP2</i> or other transporter activities involved in methotrexate clearance. British Journal of Clinical Pharmacology, 2014, 78, 329-342.	2.4	16
126	Small Molecule-Mediated Directed Differentiation of Human Embryonic Stem Cells Toward Ventricular Cardiomyocytes. Stem Cells Translational Medicine, 2014, 3, 18-31.	3.3	141



#	ARTICLE	IF	CITATIONS
127	Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1049-1057.	1.9	9
128	Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. <i>Circulation Research</i> , 2014, 114, 1929-1943.	4.5	79
129	Cardiac myocyteâ€‘secreted cAMP exerts paracrine action via adenosine receptor activation. <i>Journal of Clinical Investigation</i> , 2014, 124, 5385-5397.	8.2	70
130	Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 317-323.	4.7	795
131	An Allele-Specific PCR System for Rapid Detection and Discrimination of the CYP2C19âˆ—4A, âˆ—4B, and âˆ—17 Alleles. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 783-789.	2.8	17
132	Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. <i>Pharmacogenomics Journal</i> , 2013, 13, 507-513.	2.0	40
133	Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. <i>Pharmacogenomics Journal</i> , 2013, 13, 369-377.	2.0	87
134	The CLIPMERGE PGx Program: Clinical Implementation of Personalized Medicine Through Electronic Health Records and Genomicsâ€‘Pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 214-217.	4.7	144
135	Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1786-1792.	0.9	160
136	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	2.2	3,915
137	Cyclic Nucleotide Compartmentalization: Contributions of Phosphodiesterases and ATP-Binding Cassette Transporters. <i>Annual Review of Pharmacology and Toxicology</i> , 2013, 53, 231-253.	9.4	71
138	Influence of Genetic Variations on Levels of Inflammatory Markers of Healthy Subjects at Baseline and One Week after Clopidogrel Therapy; Results of a Preliminary Study. <i>International Journal of Molecular Sciences</i> , 2013, 14, 16402-16413.	4.1	1
139	Myocardial Delivery of Stromal Cell-Derived Factor 1 in Patients With Ischemic Heart Disease. <i>Circulation Research</i> , 2013, 112, 746-747.	4.5	5
140	Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 128, 512-523.	1.6	97
141	Pulmonary Hypertension: Novel Pathways and Emerging Therapies Inhibitors of cGMP and cAMP Metabolism. <i>Handbook of Experimental Pharmacology</i> , 2013, , 513-529.	1.8	3
142	STIM1 and Orai in cardiac hypertrophy and vascular proliferative diseases Anne-Marie Lompre. <i>Frontiers in Bioscience - Scholar</i> , 2013, S5, 766-773.	2.1	11
143	Comment amÃ©liorer l'adhÃ©sion au traitement du malade atteint de lupus Ã©rythÃ©mateux ?. , 2013, , 239-240.		0
144	Wytyczne ESC dotyczÄ…ce postÄ™powania w stabilnej chorobie wieÅ„cowej w 2013 roku. <i>Kardiologia Polska</i> , 2013, 71, 243-318.	0.6	3

#	ARTICLE	IF	CITATIONS
145	Pulmonary Hypertension: Novel Pathways and Emerging Therapies Inhibitors of cGMP and cAMP Metabolism. Handbook of Experimental Pharmacology, 2013, 218, 513-529.	1.8	2
146	Plasticity of Surface Structures and Î² <sub>2</sub> -Adrenergic Receptor Localization in Failing Ventricular Cardiomyocytes During Recovery From Heart Failure. Circulation: Heart Failure, 2012, 5, 357-365.	3.9	102
147	Clopidogrel and CYP2C19 Testing: Ready for Clinical Prime Time?. Clinical Chemistry, 2012, 58, 154-157.	3.2	7
148	High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. European Heart Journal, 2012, 33, 1241-1249.	2.2	127
149	Blockbuster interactions: are they bad for the patient?. European Heart Journal, 2012, 33, 2121-2123.	2.2	0
150	Pharmacogenetics of Clopidogrel. Current Pharmaceutical Design, 2012, 18, 5309-5327.	1.9	16
151	PharmGKB summary. Pharmacogenetics and Genomics, 2012, 22, 159-165.	1.5	141
152	Sarcoplasmic reticulum and calcium cycling targeting by gene therapy. Gene Therapy, 2012, 19, 596-599.	4.5	11
153	Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes. FASEB Journal, 2012, 26, 1009-1017.	0.5	61
154	Stem Cell Factor Gene Transfer Promotes Cardiac Repair After Myocardial Infarction via In Situ Recruitment and Expansion of c-kit <sup>+</sup> Cells. Circulation Research, 2012, 111, 1434-1445.	4.5	63
155	Preclinical animal models for testing iPSC/ESC-based heart therapy. Drug Discovery Today: Disease Models, 2012, 9, e229-e236.	1.2	2
156	RÃ©sistance au clopidogrel, tests gÃ©nÃ©tiques et tests fonctionnels. Archives of Cardiovascular Diseases Supplements, 2012, 4, 209-216.	0.0	0
157	STIM1 silencing prevents pressureâ€œload induced cardiac hypertrophy in mice. FASEB Journal, 2012, 26, 137.7.	0.5	0
158	Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clinical Pharmacology and Therapeutics, 2011, 90, 328-332.	4.7	422
159	Genetic substudy of the PLATO trial. Lancet, The, 2011, 377, 637.	13.7	13
160	Genetic substudy of the PLATO trial â€œ Authors' reply. Lancet, The, 2011, 377, 637-638.	13.7	6
161	FXIII-A Leu34 genetic variant in premature coronary artery disease: A genotype â€œ phenotype case control study. Thrombosis and Haemostasis, 2011, 106, 511-520.	3.4	16
162	<i>CYP2C19</i> But Not <i>PON1</i> Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Postâ€œMyocardial Infarction Patients. Circulation: Cardiovascular Interventions, 2011, 4, 422-428.	3.9	110

#	ARTICLE	IF	CITATIONS
163	Thienopyridine-Associated Drug-Drug Interactions: Pharmacologic Mechanisms and Clinical Relevance. <i>Current Cardiology Reports</i> , 2011, 13, 451-458.	2.9	11
164	The <i>COMT</i> Val158Met polymorphism affects the response to entacapone in Parkinson's disease: A randomized crossover clinical trial. <i>Annals of Neurology</i> , 2011, 69, 111-118.	5.3	82
165	High Doses of Clopidogrel to Overcome Genetic Resistance. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 392-402.	2.9	118
166	Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1765-74.	7.4	179
167	Critical Role for Stromal Interaction Molecule 1 in Cardiac Hypertrophy. <i>Circulation</i> , 2011, 124, 796-805.	1.6	144
168	Urinary Elimination of Coproporphyrins Is Dependent on <i>ABCC2</i> Polymorphisms and Represents a Potential Biomarker of MRP2 Activity in Humans. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-9.	3.0	20
169	Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 2888-2897.	8.2	83
170	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. <i>Arthritis and Rheumatism</i> , 2010, 62, 2047-2054.	6.7	85
171	Effect of an increased clopidogrel maintenance dose or lansoprazole coadministration on the antiplatelet response to clopidogrel in <i>CYP2C19</i> genotyped healthy subjects. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 610-613.	3.8	36
172	Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 367-375.	2.4	9
173	The Inhibition Of MRP4, A New Target In Pulmonary Arterial Hypertension, Prevents And Reverses Hypoxia-induced Pulmonary Hypertension In Mice. , 2010, , .		0
174	Reduced-Function <i>CYP2C19</i> Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1821.	7.4	980
175	Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 <i>2C19</i> *2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration. <i>Journal of the American College of Cardiology</i> , 2010, 56, 134-143.	2.8	348
176	Antiplatelet Therapy and Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2010, 56, 2003-2005.	2.8	5
177	Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. <i>Lancet</i> , The, 2010, 376, 1476-1484.	13.7	330
178	Pharmacogenomics and personalized medicine: lost in translation?. <i>Genome Medicine</i> , 2010, 2, 13.	8.2	8
179	DÃ©terminants gÃ©nÃ©tiques de la rÃ©ponse au clopidogrel. <i>Hematologie</i> , 2009, 15, 113-116.	0.0	0
180	Genetic Variants of the Î±-Synuclein Gene <i>SNCA</i> Are Associated with Multiple System Atrophy. <i>PLoS ONE</i> , 2009, 4, e7114.	2.5	144

#	ARTICLE	IF	CITATIONS
181	Can We Override Clopidogrel Resistance?. <i>Circulation</i> , 2009, 119, 2854-2857.	1.6	115
182	Multi-drug Resistance Protein 4 (MRP4/ABCC4) and cyclic nucleotides signaling pathways. <i>Cell Cycle</i> , 2009, 8, 959-964.	2.6	13
183	Stent thrombosis: who's guilty?. <i>European Heart Journal</i> , 2009, 30, 2685-2688.	2.2	16
184	RNA Interference Targeting STIM1 Suppresses Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat. <i>Molecular Therapy</i> , 2009, 17, 455-462.	8.2	82
185	Personalized medicine for clopidogrel resistance?. <i>Nature Reviews Cardiology</i> , 2009, 6, 334-336.	13.7	24
186	Role of sarco/endoplasmic reticulum calcium content and calcium ATPase activity in the control of cell growth and proliferation. <i>Pflugers Archiv European Journal of Physiology</i> , 2009, 457, 673-685.	2.8	78
187	Quantification of coproporphyrin isomers I and III in urine by HPLC and determination of their ratio for investigations of Multidrug Resistance Protein 2 (MRP2) function in humans. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 3893-3898.	2.3	10
188	The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1409-1411.	3.8	114
189	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. <i>Lancet, The</i> , 2009, 373, 309-317.	13.7	864
190	Cytochrome P450 2C19 polymorphism and clopidogrel after MI â€” Authors' reply. <i>Lancet, The</i> , 2009, 373, 1172-1173.	13.7	11
191	Therapeutic Drug Monitoring of Clozapine in a Hemodialysed Smoking Patient With Schizophrenia. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 281-282.	2.0	8
192	Multi-drug resistance protein 4 (MRP4/ABCC4) and cyclic nucleotides signaling pathways. <i>Cell Cycle</i> , 2009, 8, 962-3.	2.6	8
193	Changes in Enoxaparin Pharmacokinetics During Pregnancy and Implications for Antithrombotic Therapeutic Strategy. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 370-377.	4.7	98
194	Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Systemic Lupus Erythematosus and Design of Bayesian Estimator Using Limited Sampling Strategies. <i>Clinical Pharmacokinetics</i> , 2008, 47, 277-284.	3.5	48
195	Comment Ã©viter les piÃ©ges des essais de non-infÃ©rioritÃ© ?. <i>JEUR/Journal EuropÃ©en Des Urgences</i> , 2008, 21, 5-7.	0.0	0
196	Downregulation of the calcium current in human right atrial myocytes from patients in sinus rhythm but with a high risk of atrial fibrillation. <i>European Heart Journal</i> , 2008, 29, 1190-1197.	2.2	58
197	Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation. <i>Journal of Clinical Investigation</i> , 2008, 118, 2747-2757.	8.2	105
198	Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. <i>European Heart Journal</i> , 2007, 28, 457-462.	2.2	168

#	ARTICLE	IF	CITATIONS
199	Cardiomyopathy Related to Antimalarial Therapy with Illustrative Case Report. <i>Cardiology</i> , 2007, 107, 73-80.	1.4	103
200	Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1547-1548.	0.9	28
201	Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 821-824.	0.9	176
202	Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. <i>Rheumatology</i> , 2007, 46, 808-810.	1.9	124
203	Reply to Ray and Cihlar. <i>Journal of Infectious Diseases</i> , 2007, 195, 1390-1391.	4.0	2
204	Hydroxychloroquine in systemic lupus erythematosus. <i>Lancet</i> , The, 2007, 369, 1257-1258.	13.7	31
205	Potentialisation de fluindione et de warfarine par dexamÃ©thasone dans le myÃ©lome multiple et l'amylose AL. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 845-851.	0.0	0
206	Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2153-2155.	3.8	117
207	Potentialisation de fluindione ou de warfarine par la dexamÃ©thasone dans le myÃ©lome multiple et l'amylose AL. <i>Joint Bone Spine</i> , 2007, 74, 446-452.	1.6	18
208	Association between ABCC2 Gene Haplotypes and Tenofovir-Induced Proximal Tubulopathy. <i>Journal of Infectious Diseases</i> , 2006, 194, 1481-1491.	4.0	230
209	Renal Tubular Drug Transporters. <i>Nephron Physiology</i> , 2006, 103, p97-p106.	1.2	102
210	Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. <i>Blood</i> , 2006, 108, 2244-2247.	1.4	854
211	Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. <i>Fundamental and Clinical Pharmacology</i> , 2006, 20, 321-330.	1.9	22
212	Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 626-633.	2.3	41
213	Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 3284-3290.	6.7	274
214	A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 277-285.	1.5	125
215	Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 542-552.	4.7	66
216	Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 364-373.	2.4	31

#	ARTICLE	IF	CITATIONS
217	Corrected QT interval in anti-SSA-positive adults with connective tissue disease: Comment on the article by Lazzarini et al. <i>Arthritis and Rheumatism</i> , 2005, 52, 676-677.	6.7	28
218	Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: A combined analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 212-221.	1.7	30
219	Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 409-416.	1.9	54
220	Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 743-746.	0.7	182
221	Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. <i>European Heart Journal</i> , 2004, 25, 1788-1796.	2.2	97
222	Renal safety of tenofovir in HIV treatment-experienced patients. <i>Aids</i> , 2004, 18, 1074-1076.	2.2	153
223	Natural History and Risk Stratification of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. <i>Circulation</i> , 2004, 110, 1879-1884.	1.6	387
224	Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. <i>Kidney International</i> , 2004, 66, 1153-1158.	5.2	138
225	Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. <i>Fundamental and Clinical Pharmacology</i> , 2004, 18, 113-123.	1.9	57
226	Nelfinavir and felodipine: a cytochrome P450 3A4-mediated drug interaction. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 362-363.	4.7	13
227	Effect of Renal Function on the Pharmacokinetics of Enoxaparin and Consequences on Dose Adjustment. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 305-310.	2.0	52
228	Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathies. , 2004, , 588-600.		8
229	Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 299-306.	2.4	9
230	Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. <i>American Heart Journal</i> , 2003, 146, 729-735.	2.7	48
231	Differential Effects of Lipid-Lowering Therapies on Stroke Prevention. <i>Archives of Internal Medicine</i> , 2003, 163, 669.	3.8	137
232	Influence of endogenous oestrogens on QT interval duration. <i>European Heart Journal</i> , 2003, 24, 1663-1667.	2.2	52
233	Beta-blocker benefit according to severity of heart failure. <i>European Journal of Heart Failure</i> , 2003, 5, 281-289.	7.1	25
234	Spontaneous renal CT-scan hyperdensity of an HIV-associated nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2678-2678.	0.7	0

#	ARTICLE	IF	CITATIONS
235	DIFFERENTIAL EFFECTS OF LIPID-LOWERING THERAPIES ON STROKE PREVENTION. Evidence-Based Eye Care, 2003, 4, 148-149.	0.2	2
236	Beta-blocker treatment in heart failure. Fundamental and Clinical Pharmacology, 2001, 15, 95-109.	1.9	31
237	Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial. Circulation, 2001, 103, 1428-1433.	1.6	461
238	Feasibility and safety of ultrasound-aided thoracentesis in mechanically ventilated patients. Intensive Care Medicine, 1999, 25, 955-958.	8.2	270